Navigation Links
Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results
Date:2/27/2008

s planned New Drug Application

submission to the FDA and for commercialization of lorcaserin after

regulatory marketing approval. The agreements included a long-term

supply agreement for Arena's purchase of lorcaserin active

pharmaceutical ingredient, or API, the purchase of certain finishing

facility assets and technology, including fixtures, equipment, other

personal property and real estate assets, a contract manufacturing

agreement whereby Arena will manufacture certain products for

Siegfried, and a services agreement.

-- Reported positive Phase 1a clinical trial results of APD791, Arena's

oral, internally discovered drug candidate intended for the treatment

and prevention of arterial thromboembolic diseases, and initiated a

Phase 1b clinical trial to further evaluate this drug candidate.

-- Announced that initial clinical trial results for APD668, an oral drug

candidate discovered by Arena and investigated for the treatment of

type 2 diabetes under its partnership with Ortho-McNeil, suggest that

the Glucose-Dependent Insulinotropic Receptor, or GDIR, may improve

glucose control in patients with type 2 diabetes. Based on the data

from those studies, Ortho-McNeil put APD668 on hold and has advanced a

potentially more potent Arena-discovered GDIR agonist into preclinical

development.

Outlook for 2008

Arena expects to use cash, cash equivalents and short-term investments of approximately $190 to $210 million for its operating activities in 2008 and approximately $38 to $44 million for capital expenditures, which includes the cash payable at closing for the acquisition from Siegfried Ltd of a drug product finishing facility and related assets, which closed in January 2008. This assumes that Arena, and not a partner, continues to advance and fund its planned 20
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Arena Pharmaceuticals to Present at the Bear Stearns 20th Annual Healthcare Conference
2. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review
3. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review
4. Arena Pharmaceuticals Selected to Join New NASDAQ NeuroInsights Neurotech Index
5. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Arena Pharmaceuticals to Report Third Quarter 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, October 17, 2007
7. Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results
8. Arena Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Arena Pharmaceuticals Appoints Phillip M. Schneider and Randall E. Woods to Board of Directors
10. Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity
11. Arena Pharmaceuticals Enters Into Strategic Agreements for the Manufacture of Pharmaceutical Material, Including Lorcaserin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... , May 27, 2015 Research ... addition of Jain PharmaBiotech,s new report ... their offering. An increasing use ... industries is anticipated. Nanotechnology will be applied ... from formulations for optimal delivery to diagnostic ...
(Date:5/28/2015)... May 28, 2015 The Academy of Model ... Aviation Day on August 15, 2015. National Model Aviation Day ... and to introduce model flying to the general public. , ... clubs to participate in the celebration by hosting events in ... host National Model Aviation Day events. View our online ...
(Date:5/28/2015)... TX (PRWEB) May 28, 2015 ... association serving and representing the life sciences industry ... Board of Directors meeting at The Foundry in ... of the organization brought together a broad spectrum ... and underscored the organization's early successes in partnering ...
(Date:5/28/2015)... GAITHERSBURG, Md. , May 28, 2015  GenVec, ... president and CEO, Douglas J. Swirsky , will ... Healthcare Conference at 11 a.m. EDT on Thursday, June ... webcast of Mr. Swirsky,s presentation will be available at ... also be available on GenVec,s website.  To access, visit ...
Breaking Biology Technology:Global Nanobiotechnology Market 2015-2024 - Applications, Markets and Companies 2Global Nanobiotechnology Market 2015-2024 - Applications, Markets and Companies 3Model flying pilots celebrate the Academy of Model Aeronautics Foundation’s Third Annual National Model Aviation Day 2BioNorthTX Holds Inaugural Board of Directors Meeting 2BioNorthTX Holds Inaugural Board of Directors Meeting 3GenVec To Present At The Jefferies Healthcare Conference 2
... YORK , Feb. 10 Intellect ... company focused on development of disease-modifying therapeutic agents for ... significant shareholders (the "Interested Shareholders") have agreed in principle ... the Company in its efforts to restructure its balance ...
... YORK , Feb. 10 DuPont (NYSE: ... he expects the DuPont Agriculture & Nutrition segment to grow sales ... across the seed, crop protection, and nutrition and health businesses.   ... is paying off," Borel said at the Goldman Sachs 14th Annual ...
... Additional AeroLEF patents granted in Europe , China ... Feb. 10 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE ... additional patents in the US for AeroLEF(R), the Company,s proprietary, ... the treatment of moderate to severe acute pain. US patent ...
Cached Biology Technology:Intellect Neurosciences, Inc. Announces Preliminary Agreement with Significant Shareholders to Provide Interim Funding and Assist the Company in Efforts to Secure Additional Financing 2Intellect Neurosciences, Inc. Announces Preliminary Agreement with Significant Shareholders to Provide Interim Funding and Assist the Company in Efforts to Secure Additional Financing 3Intellect Neurosciences, Inc. Announces Preliminary Agreement with Significant Shareholders to Provide Interim Funding and Assist the Company in Efforts to Secure Additional Financing 4DuPont Expects Strong 2010 Agriculture & Nutrition Sales Growth, Margin Expansion 2DuPont Expects Strong 2010 Agriculture & Nutrition Sales Growth, Margin Expansion 3DuPont Expects Strong 2010 Agriculture & Nutrition Sales Growth, Margin Expansion 4DuPont Expects Strong 2010 Agriculture & Nutrition Sales Growth, Margin Expansion 5YM BioSciences granted two US patents for AeroLEF(R) 2YM BioSciences granted two US patents for AeroLEF(R) 3YM BioSciences granted two US patents for AeroLEF(R) 4
(Date:5/5/2015)... May 5, 2015, NXT-ID, Inc. (NASDAQ: NXTD ... on the growing mobile commerce market, reminds investors and media ... Officer, is presenting  at CARTES SECURE CONNEXIONS AMERICA 2015, held ... The three-day conference is organized into a ... in is themed Global Fraud: Where is the Trust ...
(Date:4/27/2015)... LAUDERDALE, Fla. , Apr. 27, 2015 ... of access control and security systems is pleased to ... the company as a consultant and member of its ... is widely known as a thought leader in ... Distance Learning Technology Group, and has published studies and ...
(Date:4/20/2015)... 20, 2015 The announcement comes ... Glenbeigh Records Management (GRM), Ireland,s foremost ... Bank. Having built up an impressive track record of clients ... player within the records management sector in Dubai ... is GCC staffbase and employ a further eight staff members ...
Breaking Biology News(10 mins):NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3
... Cell DNA is a news aggregator that compiles life ... them online, and in a daily email digest format, free ... digests, readers can comment on, or tweet their favorite news ... subscribe to receive daily news direct to their email in-box ...
... Powdery mildew is a fungus that infects both crop ... pathogens cause immense crop loss. Despite decades of intense research, ... hyphae to invade the host,s epidermal cells. A European research ... University of Zurich, now published a study in Science ...
... November 2010 The Aeras Global TB Vaccine Foundation ... Foreign Affairs has renewed its funding to Aeras with ... years (2011-2014) to further its efforts to develop new ... This expression of support represents a ...
Cached Biology News:Fertility or powdery mildew resistance? 2Fertility or powdery mildew resistance? 3Aeras awarded €11.7 million ($16 million) grant from Dutch government 2
... PGF2α) is a metabolite of the ... monkeys and humans. 8-iso PGF2α is ... peroxidation. In both humans and monkeys, ... to metabolites having 2 or 4 ...
kismet (dK-20)...
...
Porcine Pulmonary Artery Endothelial Cells (PPAEC) (>500,000 cells)...
Biology Products: